Team:Penn/LightActivatedOverview
From 2012.igem.org
(126 intermediate revisions not shown) | |||
Line 1: | Line 1: | ||
{{:Team:Penn/Template/Site}} | {{:Team:Penn/Template/Site}} | ||
<html> | <html> | ||
+ | <style type="text/css"> | ||
+ | .all{ width:1000px; margin:0 auto;} | ||
+ | .ImageBorder {border: 3px solid #ffffff;margin: 0 0 20px 0;} | ||
+ | .und{font-size:20px;color:white; text-align:center; margin:20px 0 20px 0;} | ||
+ | .bigbox{width:936px; padding:30px;background:#d7dce1;border:2px solid #708090;border-radius:10px;-moz-border-radius:10px;-webkit-border-radius:10px;color:black; font-size:14px; text-align:justify; margin:0 0 20px 0;} | ||
+ | .smallbox{ margin:20px auto; width:600px; padding:40px;background:#d7dce1;border:2px solid #708090;border-radius:10px;-moz-border-radius:10px;-webkit-border-radius:10px; overflow:hidden; text-align:justify;} | ||
+ | .pic1{ float:left; margin:0 40px 0 0; width:150px;} | ||
+ | .name{ font-size:20px;} | ||
+ | .figs2{width:916px; margin:0 auto; overflow:hidden;} | ||
+ | .fignew{font-size:13px; width:418px; margin:10px auto; float:left; padding:0 20px 0 20px;} | ||
+ | .fig{font-size:13px; width:500px; margin:10px auto;} | ||
+ | </style> | ||
+ | <br> | ||
- | < | + | <div style="text-align:center;font-size:34px;color:white;"><b>Light-Activated Cell Lysis </b></div> |
+ | <br> | ||
+ | <div class="bigbox"> | ||
+ | <b><div class="name" align="center">Objectives</div></b><br> | ||
+ | <div align="center"><img src="https://static.igem.org/mediawiki/2012/f/fc/Lightdispschematic.gif" height="525" width="700" /></div> | ||
<br> | <br> | ||
- | < | + | <p style="color:black;text-indent:30px;">In order to develop a module for light activated cell lysis, we had to implement two elements: |
+ | <ol style="font-size:15px"><li><b>Construct a light-activation system that can express a downstream gene of interest.</b></li> | ||
+ | <li><b>Express a cytolytic protein that can be expressed as our therapeutic drug to lyse cancer cells.</b></li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | <div class="bigbox"> | ||
+ | <b><div class="name" align="center">Objective 1: Light-Activated Sensor</div></b><br><br> | ||
+ | <b><div class="name" align="center" style="font-size:16px;">Selection of YF1/FixJ Blue Light Sensor</div></b><br> | ||
+ | <p style="color:black;text-indent:30px;">After reading many papers to select an appropriate light-sensing system to use, we selected the YF1/FixJ blue light system. We had also considered the red light sensor Cph8 but ultimately decided on YF1/FixJ because of its high on/off ratio of gene expression and also because of its availability to us (we were fortunate enough to come across the YF1/FixJ system in the form of the pDawn plasmid from the Moglich lab in Germany).</p><br> | ||
+ | <b><div class="name" align="center" style="font-size:16px;">YF1/FixJ System (pDawn)</div></b> | ||
<br> | <br> | ||
- | + | <p style="color:black;text-indent:30px;">As shown below in Figure 1, the YF1/FixJ system works through a "repress the repressor" concept. Upon 480 nm blue light illumination, YF1 (a fusion of a LOV protein domain and a histidine kinase) phosphorylates a FixJ response regulator that activates the pFixK2 promoter. The activation of pFixK2, promotes expression of the cI repressor that, in turn, represses the lambda promoter pR. The net result is activation of the gene in the downstream MCS. </p><br> | |
- | < | + | <div align="center"><img src="https://static.igem.org/mediawiki/2012/7/74/PDAWN.gif" /> |
- | < | + | |
- | <div | + | |
- | < | + | |
- | + | ||
- | + | ||
- | + | ||
</div> | </div> | ||
<br> | <br> | ||
+ | <div style="text-align:center"><b>Figure 1</b><br /></div> | ||
+ | </div> | ||
+ | <div class="bigbox"> | ||
+ | <b><div class="name" align="center">Objective 2: Expression of a Cytolytic Protein</div></b><br> | ||
+ | <b><div class="name" align="center">Cytolysin A (ClyA)</div></b><br> | ||
+ | <p style="color:black;text-indent:30px;"> | ||
+ | ClyA is a protein native to E. coli, Shigella flexneri, and Salmonella typhi that is capable of forming 13-mer pore complexes in a redox-independent manner. Expression of clyA in the absence of other hemolytic toxins is sufficient to induce hemolysis experimentally, and is therefore considered to be a potent cytolytic agent. Unlike a similar protein, HlyA, ClyA is not synthesized as a protoxin, which requires further posttranslational modifications to become active. ClyA is functional immediately following translation of mRNA to protein. | ||
- | + | ClyA is a 34kDa protein that is composed primarily of α-helical bundles that form a rod-shaped molecule. The membrane insertion domain is known as a β tongue (shown in yellow in Figure 2) and is critical for hemolytic activity. If the β tongue is mutated, the hemolytic activity of clyA is abrogated. </p> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
<br> | <br> | ||
- | <div | + | <div class="fig"><div align="center"><img src="https://static.igem.org/mediawiki/2012/2/22/ClyAPoregif.gif" /><br> |
- | + | <br><b>Figure 2</b></div>Figure 2: ClyA forms a 13-mer pore complex that consists of hydrophobic beta tongues (yellow) on the head domains of individual monomer units that play an important role in influencing its cytolytic functions. | |
- | < | + | |
- | + | ||
- | <img src="https://static.igem.org/mediawiki/2012/ | + | |
- | < | + | |
- | < | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
</div> | </div> | ||
<br> | <br> | ||
- | + | <b><div class="name" align="center">Mechanism of Action</div></b> | |
- | < | + | |
- | + | ||
- | + | ||
<br> | <br> | ||
- | <p style="color:black;text-indent:30px;"> | + | <p style="color:black;text-indent:30px;">We selected ClyA as our cytolytic protein because of its unique mechanism of action that makes it especially potent. ClyA is secreted from bacteria in outer membrane vesicles (OMV's), within which it forms pore assemblies. As shown below in Figure 3, these pore assemblies allow ClyA to latch on to the cell wall of other cells and through the use of its encapsulating pore assembly lyse the cell wall. </p><br> |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | < | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
+ | <div class="fig"><div align="center"><img src="https://static.igem.org/mediawiki/2012/6/6c/ClyA-Pore-Assembly.jpg" /><br> | ||
+ | <br><b>Figure 3</b></div>Figure 3: Shown above in the first image are pore assemblies containing 13-mers of ClyA interacting with the surface of the target membrane. The second image below shows the ClyA assembly lysing the cell membrane through pore formation. (Wallace et. al 2000) | ||
+ | </div> | ||
</body> | </body> | ||
- | |||
</html> | </html> |
Latest revision as of 03:32, 27 October 2012
In order to develop a module for light activated cell lysis, we had to implement two elements:
- Construct a light-activation system that can express a downstream gene of interest.
- Express a cytolytic protein that can be expressed as our therapeutic drug to lyse cancer cells.
After reading many papers to select an appropriate light-sensing system to use, we selected the YF1/FixJ blue light system. We had also considered the red light sensor Cph8 but ultimately decided on YF1/FixJ because of its high on/off ratio of gene expression and also because of its availability to us (we were fortunate enough to come across the YF1/FixJ system in the form of the pDawn plasmid from the Moglich lab in Germany).
As shown below in Figure 1, the YF1/FixJ system works through a "repress the repressor" concept. Upon 480 nm blue light illumination, YF1 (a fusion of a LOV protein domain and a histidine kinase) phosphorylates a FixJ response regulator that activates the pFixK2 promoter. The activation of pFixK2, promotes expression of the cI repressor that, in turn, represses the lambda promoter pR. The net result is activation of the gene in the downstream MCS.
ClyA is a protein native to E. coli, Shigella flexneri, and Salmonella typhi that is capable of forming 13-mer pore complexes in a redox-independent manner. Expression of clyA in the absence of other hemolytic toxins is sufficient to induce hemolysis experimentally, and is therefore considered to be a potent cytolytic agent. Unlike a similar protein, HlyA, ClyA is not synthesized as a protoxin, which requires further posttranslational modifications to become active. ClyA is functional immediately following translation of mRNA to protein. ClyA is a 34kDa protein that is composed primarily of α-helical bundles that form a rod-shaped molecule. The membrane insertion domain is known as a β tongue (shown in yellow in Figure 2) and is critical for hemolytic activity. If the β tongue is mutated, the hemolytic activity of clyA is abrogated.
Figure 2
We selected ClyA as our cytolytic protein because of its unique mechanism of action that makes it especially potent. ClyA is secreted from bacteria in outer membrane vesicles (OMV's), within which it forms pore assemblies. As shown below in Figure 3, these pore assemblies allow ClyA to latch on to the cell wall of other cells and through the use of its encapsulating pore assembly lyse the cell wall.
Figure 3